Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
7.50 x 2 10.50 x 1
Pre-market by (Cboe BZX)
9.22 +0.61 (+7.08%) 04/22/25 [NASDAQ]
7.50 x 2 10.50 x 1
Pre-market 8.92 -0.30 (-3.25%) 05:01 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.52
Day High
9.30
Open 8.74
Previous Close 8.61 8.61
Volume 1,137,200 1,137,200
Avg Vol 1,012,455 1,012,455
Stochastic %K 92.73% 92.73%
Weighted Alpha -27.95 -27.95
5-Day Change +1.66 (+21.96%) +1.66 (+21.96%)
52-Week Range 5.35 - 17.58 5.35 - 17.58
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 465,612
  • Shares Outstanding, K 54,078
  • Annual Sales, $ 36,560 K
  • Annual Income, $ -88,980 K
  • EBIT $ -101 M
  • EBITDA $ -101 M
  • 60-Month Beta 1.09
  • Price/Sales 11.38
  • Price/Cash Flow N/A
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 125.26% ( -4.70%)
  • Historical Volatility 82.64%
  • IV Percentile 83%
  • IV Rank 49.29%
  • IV High 216.89% on 03/10/25
  • IV Low 36.18% on 08/20/24
  • Put/Call Vol Ratio 0.42
  • Today's Volume 111
  • Volume Avg (30-Day) 60
  • Put/Call OI Ratio 2.68
  • Today's Open Interest 1,614
  • Open Int (30-Day) 1,835

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.21
  • Low Estimate -0.57
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +35.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.35 +72.34%
on 04/09/25
Period Open: 8.15
9.30 -0.86%
on 04/22/25
+1.07 (+13.13%)
since 03/21/25
3-Month
5.35 +72.34%
on 04/09/25
Period Open: 10.02
12.98 -28.97%
on 02/05/25
-0.80 (-7.98%)
since 01/22/25
52-Week
5.35 +72.34%
on 04/09/25
Period Open: 11.25
17.58 -47.55%
on 06/13/24
-2.03 (-18.04%)
since 04/22/24

Most Recent Stories

More News
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

AKBA : 2.14 (+3.38%)
STOK : 9.22 (+7.08%)
ACAD : 14.35 (-0.21%)
BIIB : 118.89 (+2.06%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,287.76 (+2.51%)
STOK : 9.22 (+7.08%)
ACAD : 14.35 (-0.21%)
PHAT : 3.96 (+1.54%)
BIIB : 118.89 (+2.06%)
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...

CTMX : 0.7361 (-1.84%)
VYGR : 3.37 (+4.98%)
CSTL : 21.98 (+3.97%)
STOK : 9.22 (+7.08%)
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

CDXC : 7.87 (-0.88%)
ADMA : 21.39 (+8.91%)
TARS : 49.44 (+1.92%)
STOK : 9.22 (+7.08%)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 7.87 (-0.88%)
ADMA : 21.39 (+8.91%)
TARS : 49.44 (+1.92%)
STOK : 9.22 (+7.08%)
Insider Sale: CEO of $STOK (STOK) Sells 6,786 Shares

Edward M. MD Kaye, the CEO of $STOK ($STOK), sold 6,786 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.9% of their shares....

STOK : 9.22 (+7.08%)
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares

Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 13,945 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.8%...

STOK : 9.22 (+7.08%)
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...

IMCR : 29.52 (+0.37%)
CSTL : 21.98 (+3.97%)
STOK : 9.22 (+7.08%)
SPRO : 0.7322 (+0.99%)
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 10,000 Shares

Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 10,000 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.3%...

STOK : 9.22 (+7.08%)
Stocks Inch Higher After February's US Durable Goods Orders Released

Stocks are slightly up this morning as market participants reacted to February's US Durable Goods Report.

UAL : 66.97 (+2.56%)
NDAQ : 72.69 (+2.87%)
TNDM : 16.35 (-0.24%)
$SPX : 5,287.76 (+2.51%)
$IUXX : 18,276.41 (+2.63%)
MCD : 319.08 (+3.36%)
DIS : 86.09 (+2.49%)
QQQ : 444.48 (+2.63%)
OCDO.LN : 290.000 (+0.73%)
WPRT : 2.85 (+2.15%)
STX : 75.36 (+1.93%)
$DOWI : 39,186.98 (+2.66%)

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 10.29
2nd Resistance Point 9.79
1st Resistance Point 9.51
Last Price 9.22
1st Support Level 8.73
2nd Support Level 8.23
3rd Support Level 7.95

See More

52-Week High 17.58
Fibonacci 61.8% 12.91
Fibonacci 50% 11.47
Fibonacci 38.2% 10.02
Last Price 9.22
52-Week Low 5.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro